CRTX Share Price | Quince Therapeutics, Inc. Stock Analysis & Recommendation

Q: How big is Quince Therapeutics, Inc.?

Market Cap: As of Jun 18, Quince Therapeutics, Inc. has a market capitalization of 61.84 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Quince Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -60.71 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 30.15 million and total assets of 126.15 million.

Q: What does Quince Therapeutics, Inc. do?

Overview: Quince Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on providing disease-modifying therapeutics for Alzheimer’s and other degenerative diseases within the Pharmaceuticals & Biotechnology industry.Financial Snapshot: Most recent Net Profit: -15 Million (Quarterly Results - Mar 2025) Market cap: USD 61.84 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.87 Return on Equity: -206.93% Price to Book: 3.33Contact Details: Address: 269 E Grand Ave, SOUTH SAN FRANCISCO CA: 94080-4804 Tel: 1 415 9105717 Fax: 1 302 6555049 Website: https://www.cortexyme.com/

Q: Is Quince Therapeutics, Inc. technically bullish or bearish?

As of 21 August 2025, the technical trend for Quince Therapeutics, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by daily moving averages and a bullish outlook from Bollinger Bands and KST indicators. However, the weekly MACD is mildly bearish, indicating some caution. The stock has shown a strong 1-year return of 119.05%, significantly outperforming the S&P 500's 17.14%, but has underperformed over longer periods, particularly with a 5-year return of -97.19% compared to the S&P's 96.61%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

4.0 M

Shareholding (Sep 2025)

FII

0.98%

Held by 9 FIIs

DII

93.71%

Held by 6 DIIs

Promoter

0.50%

How big is Quince Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Quince Therapeutics, Inc. has a market capitalization of 61.84 million, with net sales of 0.00 million and a net profit of -60.71 million over the last four quarters. The company reported shareholder's funds of 30.15 million and total assets of 126.15 million as of Dec 24.

View full answer

What does Quince Therapeutics, Inc. do?

22-Jun-2025

Quince Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for Alzheimer’s and other degenerative diseases. As of March 2025, it has a market cap of $61.84 million and reported a net profit loss of $15 million.

View full answer

Who are in the management team of Quince Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Quince Therapeutics, Inc. includes Ms. Casey Lynch (Chairman, CEO, Co-Founder), Mr. Stephen Dominy (Co-Founder, Chief Scientific Officer), and Dr. Una Ryan (Lead Independent Director), along with several independent directors.

View full answer

Is Quince Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 21, 2025, Quince Therapeutics, Inc. has a mildly bullish trend supported by daily moving averages and Bollinger Bands, despite a mildly bearish weekly MACD, with a strong 1-year return of 119.05% compared to the S&P 500's 17.14%, but a significant 5-year underperformance of -97.19% versus the S&P's 96.61%.

View full answer

Compare Quince Therapeutics, Inc. with Similar Stocks

Marker Therapeutics, Inc.VistaGen Therapeutics, Inc.Viracta Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 181 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-8.17

Return on Equity

-4,109.16%

Price to Book

170.88

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2025)

Net Profit:

-13 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-90.87%

6 Months

-91.04%

1 Year

-90.57%

2 Years

-89.02%

3 Years

-85.39%

4 Years

-97.45%

5 Years

-99.69%

Quince Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

5.46%

EBIT to Interest (avg)

-54.25

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.87

Sales to Capital Employed (avg)

Tax Ratio

0.17%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

23.41%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.86

EV to EBIT

-0.91

EV to EBITDA

-0.92

EV to Capital Employed

15.73

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-1720.47%

ROE (Latest)

-206.93%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 7 Schemes (4.8%)

Foreign Institutions

Held by 9 Foreign Institutions (0.98%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is -143.64% vs -1.85% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-11.30",
          "val2": "-8.50",
          "chgp": "-32.94%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.40",
          "val2": "2.20",
          "chgp": "-209.09%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-13.40",
          "val2": "-5.50",
          "chgp": "-143.64%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -80.89% vs 39.26% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-36.00",
          "val2": "-24.30",
          "chgp": "-48.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-22.80",
          "val2": "-10.40",
          "chgp": "-119.23%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-56.80",
          "val2": "-31.40",
          "chgp": "-80.89%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-11.30

-8.50

-32.94%

Interest

0.00

Exceptional Items

-2.40

2.20

-209.09%

Consolidate Net Profit

-13.40

-5.50

-143.64%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is -143.64% vs -1.85% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-36.00

-24.30

-48.15%

Interest

0.00

Exceptional Items

-22.80

-10.40

-119.23%

Consolidate Net Profit

-56.80

-31.40

-80.89%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -80.89% vs 39.26% in Dec 2023

All Annual Results

Company CV

About Quince Therapeutics, Inc.

Quince Therapeutics, Inc.

Pharmaceuticals & Biotechnology

Cortexyme, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on providing disease-modifying therapeutics to treat Alzheimer’s and other degenerative diseases. The Company is focused on a infectious pathogen tied to neurodegeneration in humans and animal models. The Company’s lead drug candidate, COR388, is an orally-administered, brain-penetrating small molecule gingipain inhibitor designed for the treatment of Alzheimer’s disease. COR388 is designed to target an upstream driver of multiple Alzheimer’s pathological pathways, including amyloid beta production, inflammation and neurodegeneration, in contrast to mechanisms of action targeting downstream effects, such as amyloid plaques and tau tangles.

Company Coordinates

Company Details

269 E Grand Ave , SOUTH SAN FRANCISCO CA : 94080-4804

Tel: 1 415 9105717

https://www.cortexyme.com/

Registrar Details

Quince Therapeutics, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Quince Therapeutics, Inc.?

Watch in Real-Time

What does Quince Therapeutics, Inc. do?

Who are in the management team of Quince Therapeutics, Inc.?

Is Quince Therapeutics, Inc. technically bullish or bearish?

Compare Quince Therapeutics, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Quince Therapeutics, Inc.

Company Coordinates